BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AEterna Zentaris (AEZS) Announces Election of Directors at Its Annual Meeting of Shareholders


5/9/2013 9:38:44 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

QUÉBEC CITY, May 8, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announces the results of the vote on directors held earlier today at its annual meeting of shareholders. Issuers listed on the Toronto Stock Exchange are required to issue a news release providing this information.

Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies with regard to voting on the seven directors nominated for election as set forth in the table below:

Name of NomineeVotes For%Votes Withheld%
Marcel Aubut 2,379,194 70.8 979,320 29.2
David A. Dodd* 2,385,312 71.0 973,202 29.0
José P. Dorais 2,692,560 80.2 665,954 19.8
Carolyn Egbert 2,351,610 70.0 1,006,903 30.0
Juergen Ernst 2,339,417 69.7 1,019,097 30.3
Pierre Lapalme 2,375,050 70.7 982,964 29.3
Gérald Limoges 2,380,610 70.9 977,404 29.1
(*) The results for the proxies received regarding Mr. Dodd were originally received for the Company's former President and Chief Executive Officer and director, Prof. Juergen Engel. As announced by the Company on April 15, 2013, Mr. Dodd succeeded to Prof. Engel as President and Chief Executive Officer, and Mr. Dodd was also concurrently appointed to the Board of Directors. At the same time, the Company announced that Mr. Dodd would be one of the management director nominees for election at the Company's annual meeting of shareholders and that Management proxy holders intended to exercise the discretion granted in the proxies to vote in favour of the election of Mr. Dodd as a director at the shareholders' meeting.

All other matters at the shareholders' meeting, namely the renewal of and amendment to the Company's Stock Option Plan, the reconfirmation and approval of the Shareholder Rights Plan and the confirmation of an amendment to the Company's bylaws, were also approved by shareholders.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES